A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs
Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.
Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.
BELLINGS Intelligence Score: 10
Why it matters
The launch of a $480,000-a-year cancer drug reflects ongoing trends in drug pricing but does not directly impact credit markets, borrowing costs, or financial regulation relevant to sophisticated credit professionals.
Sources
The New York Times Business
A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs
Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.